Table 1—

Baseline characteristics of normo- and microalbuminuric patients of the Casale Monferrato Study recruited for follow-up

NormoalbuminuricMicroalbuminuricP
n677426
Age (years)67.2 ± 10.067.9 ± 10.60.22
Men273 (40.3)204 (47.9)0.01
Duration of diabetes (years)9.8 ± 6.311.1 ± 7.00.001
BMI (kg/m2)27.4 ± 4.827.8 ± 4.80.20
Antidiabetic treatment
 Diet98 (14.5)30 (7.1)<0.0001
 Oral drugs496 (73.5)299 (70.7)
 Insulin81 (12.0)94 (22.2)
CHD123 (21.5)84 (23.7)0.43
Smoker89 (13.4)60 (14.4)0.02
Ex-smoker119 (18.0)103 (24.7)
Nonsmoker454 (68.6)254 (60.9)
Hypertension554 (81.8)363 (85.2)0.08
Systolic blood pressure (mmHg)153.1 ± 21.1156.1 ± 22.50.03
Diastolic blood pressure (mmHg)87.0 ± 10.088.3 ± 10.70.03
Treatment with ACE inhibitors140 (20.7)94 (22.1)0.58
HbA1c (%)7.8 ± 2.38.4 ± 2.3<0.0001
Total cholesterol (mmol/l)5.81 ± 1.205.80 ± 1.250.85
HDL cholesterol (mmol/l)1.46 ± 0.431.42 ± 0.520.26
Triglycerides (mmol/l)1.44 (1.02–1.91)1.55 (1.07–2.15)0.02
ApoA1 (mg/dl)137.1 ± 35.5131.8 ± 29.80.01
ApoB (mg/dl)101.6 ± 35.0102.2 ± 38.60.79
Fibrinogen (g/l)3.55 ± 0.873.69 ± 0.970.01
Uric acid (μmol/l)313 ± 92323 ± 920.09
Creatinine (μmol/l)88 (74–97)90 (80–104)0.007
  • Data are means ± SD, n (%), or medians (interquartile range).